Poster Walks: Cancers of the Esophagus and Stomach

Daniela Molena, MD—Poster Walk Leader, Memorial Sloan Kettering Cancer Center

Abstract 28: Disparities associated with the receipt of palliative care in patients with metastatic gastric cancer.
First Author: Subhadeep Paul, BA

CONCLUSION: Although use of PC has increased over time, PC is underutilized in mGA. Disparities exist in receipt of PC in regard to race, gender, and education. Additional research is necessary to better optimize PC use in mGA and mitigate potential disparities.

Abstract 81: A comparison of elderly versus nonelderly patients in the CRITICS gastric cancer trial.
First Author: Astrid E Slagter, MSc

CONCLUSION: Age had a significant impact on toxicity and tolerability of preop CT, but did not affect surgical resection rates and complications. Although less elderly pts started postop treatment and elderly pts received lower dose in de CT arm, there were no differences in treatment related toxicities. Survival was not significantly different. Clinical trial information: NCT00407186

Abstract 90: Multicenter prospective observational study of QoL after palliative surgery for patients with bowel obstruction caused by peritoneal dissemination of gastric cancer.
First Author: Yuichi Ito, MD, PhD

CONCLUSION: In patients with bowel obstruction caused by peritoneal dissemination of gastric cancer, palliative surgery maintained QoL while improving solid food intake, with acceptable operative morbidity and mortality rate. Clinical trial information: 000023495.


Abstract 94: Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients. 

First Author: Kazuhiro Nishikawa

CONCLUSION: Nutritional intervention with ED at 300 kcal per day for 6–8 weeks reduced body weight loss at 1 year as well as 6-8 weeks after surgery in patients who underwent total gastrectomy. Clinical trial information: 000023455.

Abstract 136: Gastric cancer liver metastasis: Optimal management for oligo-metastatic disease.
First Author: Hiromichi Ito, MD, FACS

CONCLUSION: For well selected patients with GCLM, liver resection is an effective therapy not only to prolong disease-free time, but also to achieve cure. CEA is useful to select patients with GCLM who unlikely benefit from aggressive surgery.


Marcia Cruz-Correa, MD, PhD—Poster Walk Leader, The University of Puerto Rico and MD Anderson Cancer Center

Abstract 43: DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
First Author: Raghav Sundar, MBBS

CONCLUSION: Chemotherapy does not appear to change methylation status of EAC. Hypermethylation of RUNX1T1, CCND2 and hypomethylation of MST1R and MMP14 leads to significantly decreased benefit from chemotherapy in EA. We describe an epigenetic signature which may serve as a predictive biomarker for chemotherapy benefit using data form the largest bank of DNA methylation in EA reported to date.

Abstract 44: MSI-low is an intermediate type between MSI-high and MSS in esophagogastric junction adenocarcinoma.
First Author: Yu Imamura, FACS, MD, PhD

CONCLUSION: MSI-low cases exhibited an intermediate immune microenvironment between MSI-high and MSS, and favorable outcome. Our results may implicate MSI-low as a predictive biomarker for immune checkpoint inhibitor.


Abstract 45: Genomic profile of gastric cancer in the United States versus East Asia.
First Author: Gregory A. Gilmore, DO

CONCLUSION: This data suggests an underlying difference in the mutational profile of gastric cancers in the US as compared with Asia. These findings thus may help to describe the differences in incidence, histology, and outcomes that has been well described in the literature between these two regions of the world.

Abstract 66: MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).
First Author: Filippo Pietrantonio, MD

CONCLUSION: In resectable primary GC, MSI is an independent good prognostic marker that should be adopted as stratification factor in future RCTs. Chemotherapy omission and/or immune checkpoint blockade should be prospectively investigated in MSI-high GCs according to the clinically-defined risk of relapse.

Abstract 111: Endoscopic submucosal dissection versus surgery for undifferentiated-type early gastric cancer: A meta-analysis.
First Author: Byung-Wook Kim, MD, PhD

CONCLUSION: Despite higher recurrence rate and lower complete resection rate, ESD demonstrated similar overall survival rate and adverse event rate in the treatment of undifferentiated early gastric cancer compared to surgery.